These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27300524)

  • 1. A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
    Raizer JJ; Chandler JP; Ferrarese R; Grimm SA; Levy RM; Muro K; Rosenow J; Helenowski I; Rademaker A; Paton M; Bredel M
    J Neurooncol; 2016 Aug; 129(1):139-46. PubMed ID: 27300524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
    Odia Y; Kreisl TN; Aregawi D; Innis EK; Fine HA
    J Neurooncol; 2015 Oct; 125(1):191-5. PubMed ID: 26285768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
    McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
    J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
    Phuphanich S; Supko JG; Carson KA; Grossman SA; Burt Nabors L; Mikkelsen T; Lesser G; Rosenfeld S; Desideri S; Olson JJ
    J Neurooncol; 2010 Oct; 100(1):95-103. PubMed ID: 20213332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
    Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
    Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of an adenosine A
    Jackson S; Weingart J; Nduom EK; Harfi TT; George RT; McAreavey D; Ye X; Anders NM; Peer C; Figg WD; Gilbert M; Rudek MA; Grossman SA
    Fluids Barriers CNS; 2018 Jan; 15(1):2. PubMed ID: 29332604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
    Van Waes C; Chang AA; Lebowitz PF; Druzgal CH; Chen Z; Elsayed YA; Sunwoo JB; Rudy SF; Morris JC; Mitchell JB; Camphausen K; Gius D; Adams J; Sausville EA; Conley BA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1400-12. PubMed ID: 16005577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
    Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
    J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
    Wagner L; Marschall V; Karl S; Cristofanon S; Zobel K; Deshayes K; Vucic D; Debatin KM; Fulda S
    Oncogene; 2013 Feb; 32(8):988-97. PubMed ID: 22469979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma.
    Taylor JW; Parikh M; Phillips JJ; James CD; Molinaro AM; Butowski NA; Clarke JL; Oberheim-Bush NA; Chang SM; Berger MS; Prados M
    J Neurooncol; 2018 Nov; 140(2):477-483. PubMed ID: 30151703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
    Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
    Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
    DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
    Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
    Groves MD; Puduvalli VK; Hess KR; Jaeckle KA; Peterson P; Yung WK; Levin VA
    J Clin Oncol; 2002 Mar; 20(5):1383-8. PubMed ID: 11870183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
    Terasaki M; Bouffet E; Katsuki H; Fukushima S; Shigemori M
    Surg Neurol; 2008 Jan; 69(1):46-50. PubMed ID: 18054615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
    Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
    J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
    Conti A; Pontoriero A; Arpa D; Siragusa C; Tomasello C; Romanelli P; Cardali S; Granata F; De Renzis C; Tomasello F
    Acta Neurochir (Wien); 2012 Feb; 154(2):203-9. PubMed ID: 21984132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
    Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK
    J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.